Overview

A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular EdemaDME

Status:
RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
Phase:
PHASE2
Details
Lead Sponsor:
Innovent Biologics Technology Limited (Shanghai R&D Center)
Treatments:
faricimab
IBI302